Document Type
Article
Publication Title
Annals of Translational Medicine
Abstract
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, making up 80-85% of all lung malignancies. It can be further subdivided into different types. The three main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Traditionally, NSCLCs have been treated with a combination of chemotherapy, surgery, and/or radiation therapy. However, with the advent of genotype subtype analysis and targeted therapy it has become possible to have individualized treatment options for patients with NSCLC.
Case description: We present a case report of a 68-year-old female with NSCLC. Patient initially only received radiation therapy due to her not being a surgical candidate. While initial treatment was responsive, later imaging showed metastasis of disease. Subsequent genotype analysis of the patient's tumor indicated a MET exon 14 skipping mutation which qualified her for treatment with Capmatinib (Tabrecta).
Conclusions: Patients on Capmatinib have minimal side effects and better efficacy than traditional chemotherapy. Patients with MET exon 14 skipping mutations should be considered for Capmatinib therapy.
DOI
10.21037/atm-2022-53
Publication Date
12-2022
Keywords
Case report, MET exon 14 skipping mutation, capmatinib, non-small cell lung cancer (NSCLC), targeted therapy
ISSN
2305-5839
Recommended Citation
Clough W, Al Jaberi M, Dalia S. Non-Small Cell Lung Cancer With MET Exon 14 Skip Mutation: Case Report. Annals of Translational Medicine. 2022; 10(23). doi: 10.21037/atm-2022-53.
